Patent application number | Description | Published |
20080248308 | METHOD OF MAKING GRAPHITE-COATED PARTICULATE MATERIALS - An coated particulate is provided with a graphite-impregnated resin coating. The oil field particulates may comprise any of gravel-pack sand, granular betonite, ground Gilsonite, calcium carbonate, glass beads, rock wool, shredded paper, metal spheres, ceramic beads, nut hulls, ground rubber, plastic beads, muscovite mica, calcined petroleum coke, and perlite. The resin may comprise as a binder one or more of a natural, synthetic, water-soluble, and organic resins. More specifically, the resins may comprise an organic film-forming resin such as an alkyd, polyurethane and epoxy. Alternatively, the resin may comprise a film-forming water-soluble polymer, such as a starch, carboxymethyl cellulose, hydroxyethyl cellulose, and xanthan gum. In a further alternative, the resin may comprise a resin-dispersed emulsion, such as a latex or acrylic. | 10-09-2008 |
Patent application number | Description | Published |
20090093556 | Electronically and ionically conductive porous material and method for manufacture of resin wafers therefrom - An electrically and ionically conductive porous material including a thermoplastic binder and one or more of anion exchange moieties or cation exchange moieties or mixtures thereof and/or one or more of a protein capture resin and an electrically conductive material. The thermoplastic binder immobilizes the moieties with respect to each other but does not substantially coat the moieties and forms the electrically conductive porous material. A wafer of the material and a method of making the material and wafer are disclosed. | 04-09-2009 |
20100093049 | Biological methane production from coal, manure, sludge, wastes, or other carbonaceous feedstocks with simultaneous sequestration of co2 - The present invention provides a method for generating methane from a carbonaceous fuel source with simultaneous sequestration of carbon dioxide, the method comprising anaerobically incubating a particulate alkaline earth metal salt in contact with a particulate and/or dissolved carbonaceous feedstock in a neutral or alkaline aqueous culture medium containing a culture of methanogenic bacteria consortia and collecting methane generated therefrom. At least a portion of carbon dioxide produced during the incubation reacts with the alkaline earth metal salt to form an alkaline earth metal carbonate, thereby sequestering the carbon dioxide. | 04-15-2010 |
20130233715 | INTERNAL GAS AND LIQUID DISTRIBUTOR FOR ELECTRODEIONIZATION DEVICE - The present invention provides a resin-wafer electrodeionization (RW-EDI) apparatus including cathode and anode electrodes separated by a plurality of porous solid ion exchange resin wafers, which when in use are filled with an aqueous fluid. The apparatus includes one or more wafers comprising a basic ion exchange medium, and preferably includes one or more wafers comprising an acidic ion exchange medium. The wafers are separated from one another by ion exchange membranes. The gas and aqueous fluid are introduced into each basic wafer via a porous gas distributor which disperses the gas as micro-sized bubbles laterally throughout the distributor before entering the wafer. The fluid within the acidic and/or basic ion exchange wafers preferably includes, or is in contact with, a carbonic anhydrase (CA) enzyme or inorganic catalyst to facilitate conversion of bicarbonate ion to carbon dioxide within the acidic medium. | 09-12-2013 |
Patent application number | Description | Published |
20100261703 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG - A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed. | 10-14-2010 |
20100286397 | SALT AND CRYSTALLINE FORMS THEREOF OF A DRUG - A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed. | 11-11-2010 |
20100305125 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF - ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 12-02-2010 |
20110009325 | CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS - Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate. The rampamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof: | 01-13-2011 |
20110009618 | METHODS OF MANUFACTURING CRYSTALLING FORMS OF RAPAMYCIN ANALOGS - A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split. | 01-13-2011 |
20120028908 | Methods of Manufacturing Crystalline Forms of Rapamycin Analogs - A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split. | 02-02-2012 |
20130060040 | Salt and Crystalline Forms Thereof of a Drug - A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed. | 03-07-2013 |
20140155380 | Salt and Crystalline Forms Thereof of a Drug - A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed. | 06-05-2014 |
Patent application number | Description | Published |
20090105326 | Crystalline Chemotherapeutic - N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea·¼ Ethanolate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it is disclosed. | 04-23-2009 |
20090105486 | Crystalline Chemotherapeutic - N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea Tolueneate Crystalline Form 1, ways to make it and ways to use it are disclosed. | 04-23-2009 |
20090176784 | ANTI-INFECTIVE AGENTS AND USES THEREOF - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 07-09-2009 |
20090203664 | (1S,5S)-3-(5,6-DICHLORO-3-PYRIDINYL)-3,6- DIAZABICYCLO[3.2.0]HEPTANE - The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor. | 08-13-2009 |
20100048533 | LESTAURTINIB CRYSTALLINE FORM 1, CRYSTALLINE LESTAURIMIB ANHYDRATE AND AMORPHOUS LESTAURIMIB - Lestaurtinib Crystalline Form 1, isolated crystalline lestaurtinib anhydrate and amorphous lestaurtinib, processes to reproducibly make them and methods of treating patients using them. | 02-25-2010 |
20100048534 | CRYSTALLINE LESTAURTINIB HYDRATES AND CRYSTALLINE LESTAURTINIB HEMIHYDRATE HEMIACETONITRILEATE AND CRYSTALLINE LESTAURTINIB HEMIHYDRATE HEMITETRAHYDROFURANATE - Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemicetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate, processes to reproducibly make them and methods of treating patients using them are disclosed. | 02-25-2010 |
20100222358 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES - Octahydro-pyrrolo[3,4-b]pyrrole derivatives are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Octahydro-pyrrolo[3,4-b]pyrrole compounds, methods for using such compounds, compositions for making them, and processes for preparing such compounds are disclosed herein. | 09-02-2010 |
20110281900 | Crystalline Pharmaceutical - New crystalline forms of lopinavir are disclosed. | 11-17-2011 |
20120189580 | ANTI-INFECTIVE AGENTS AND USES THEREOF - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 07-26-2012 |
20130096132 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE - The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes. | 04-18-2013 |
20140303369 | Crystalline Pharmaceutical - New crystalline forms of lopinavir are disclosed. | 10-09-2014 |